Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I study to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of ganaxolone IV in healthy volunteers

Next Previous
Trial Profile

A phase I study to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of ganaxolone IV in healthy volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 25 Jan 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cannabidiol (Primary) ; Ganaxolone (Primary)
  • Indications Angelman syndrome; Epilepsy; Fragile X syndrome; Lennox-Gastaut syndrome; Postnatal depression; Status epilepticus
  • Focus Adverse reactions; Pharmacokinetics

    • Most Recent Events

    • 06 Dec 2022 Results presented at the 76th Annual Meeting of the American Epilepsy Society
    • 30 Nov 2022 According to Marinus Therapeutics media release, results from this trial will be presented at the upcoming 2022 American Epilepsy Society (AES) Annual Meeting.
    • 11 Oct 2022 According to Marinus Therapeutics media release, the company will present the poster presentation on "Pharmacodynamic study and effects of intravenous Ganaxolone bolus in healthy volunteers" at the 20th Neocritical Care Society Annual Meeting commencing from 17th-21st October 2022.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top